HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Cholestyramine Resin (Questran)

Subscribe to New Research on Cholestyramine Resin

A strongly basic anion exchange resin whose main constituent is polystyrene trimethylbenzylammonium Cl(-) anion.

Also Known As:

Questran; Colestyramine; Colestyramin; Cuemid; MK-135; Quantalan; Cholestyramine Resins; Cholestyramines; Colestyramines; Colestyramins; Cuemids; MK 135; MK135; Quantalans; Questrans; Resin, Cholestyramine; Resins, Cholestyramine; Cholestyramine

Networked: 667 relevant articles (91 outcomes, 97 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Beuers, Ulrich: 3 articles (01/2014 - 09/2005)
2.	Ala, Shahram: 2 articles (08/2013 - 03/2013)
3.	Beuers, U: 2 articles (12/2012 - 02/2000)
4.	Marschall, Hanns-Ulrich: 2 articles (08/2011 - 12/2006)
5.	Whitney, Edwin J: 2 articles (05/2011 - 12/2010)
6.	Krasuski, Richard A: 2 articles (05/2011 - 12/2010)
7.	Devendra, Ganesh P: 2 articles (05/2011 - 12/2010)
8.	Shepherd, J: 2 articles (08/2007 - 01/2002)
9.	Salen, Gerald: 2 articles (05/2006 - 05/2004)
10.	Napoli, C: 2 articles (01/2005 - 11/2000)

Related Diseases

1.	Diarrhea 10/01/2001 - "In this setting, cholestyramine seems to be highly effective in stopping diarrhea." 01/01/1987 - "In summary, most patients with idiopathic chronic diarrhea have bile acid malabsorption (as measured by fecal excretion of labeled bile acid), but they do not respond to cholestyramine therapy with a significant reduction in stool weight. " 05/01/2006 - "The anion-exchange resin, cholestyramine has been reported in one small case series to be an effective treatment of severe diarrhea associated with Pfiesteria intoxication. " 05/01/1988 - "Cholestyramine treatment of new born's infectious diarrhea has been shown to be effective. " 10/01/1986 - "Cholestyramine treatment of new born's infectious diarrhea has been shown to be effective. "
2.	Pruritus (Itching) 06/07/2008 - "Pruritus may represent the most distressing symptom and, when UDCA is ineffective, cholestyramine represents the mainstay of treatment. " 04/01/2011 - "Cholestyramine (n=9) and UDCA (n=8) therapy were both effective in lowering TSBA levels and lead to substantial improvement of pruritus in patients with elevated TSBA levels. " 04/01/2007 - "Pruritus represents a problem in some patients, and cholestyramine represents the first-line treatment. " 11/01/1991 - "Almost all the patients with pruritus (6 out of 7) improved with the treatment and the use of cholestyramine was reduced in all." 06/01/1982 - "Cholestyramine treatment gave incomplete relief from pruritus but resulted in no improvement in her clinical course."
3.	Hypercholesterolemia 12/01/2012 - "This study investigated the hypolipidemic effect of cocoa powder extract (CPE) in an experimental model of hypercholesterolemia, using Questran as a reference. " 02/01/1997 - "Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial." 04/26/1965 - "CHOLESTYRAMINE RESIN THERAPY FOR HYPERCHOLESTEREMIA: CLINICAL AND METABOLIC STUDIES." 06/01/2007 - "The ability of Questran, a hypolipidemic drug, to attenuate hypercholesterolemia was also examined. " 10/01/2001 - "Cholestyramine, the original drug approved for treatment of hypercholesterolemia, has previously been reported to enhance the elimination rates of a variety of toxins, presumably by interruption of enterohepatic recirculation through toxin entrapment in its polymeric structure and/or anion-exchange process. "
4.	Hyperlipoproteinemias 08/01/1990 - "It is effective in treating patients with type IIa hyperlipoproteinemia and practically has no side effects as cholestyramine." 01/01/1991 - "The tolerance and efficacy of cholestyramine (12-16 gr/day) was evaluated in 19 patients with primary type-IIa hyperlipoproteinemia. " 10/01/1994 - "The aim of our study was the biochemical and functional examination of the liver during the therapy of familiar hyperlipoproteinemia by means of MevacorR (lovostatine) in comparison with the treatment by Vasosan S (cholestyramine). " 02/01/1984 - "Thus, although the sample size does not allow a definitive conclusion to be drawn, this study suggests that cholestyramine treatment retards the rate of progression of CAD in patients with Type II hyperlipoproteinemia." 09/01/1976 - "The extended use of diet and cholestyramine therapy in familial type II hyperlipoproteinemia was examined in patients who previously participated in a short-term, double-blind trial. "
5.	Pain (Aches) 08/01/1980 - "Over a 6.5-yr period, discontinuation of cholestyramine resulted in episodes of RUQ pain and/or appearance of abnormalities in liver tests. " 08/01/2013 - "Efficacy of cholestyramine ointment in reduction of postoperative pain and pain during defecation after open hemorrhoidectomy: results of a prospective, single-center, randomized, double-blind, placebo-controlled trial: reply." 03/01/2013 - "Efficacy of cholestyramine ointment in reduction of postoperative pain and pain during defecation after open hemorrhoidectomy: results of a prospective, single-center, randomized, double-blind, placebo-controlled trial." 03/01/2013 - "The cholestyramine group had less postoperative pain than the placebo group at the 24th hour (1.84 ± 2.54 vs. 4.07 ± 3.35; P = 0.001) and 48th hour (0.18 ± 0.88 vs. 3.57 ± 3.45; P < 0.001) and less pain during defecation starting at the 48th hour (2.28 ± 2.96 vs. 4.77 ± 4.09; P = 0.001). " 09/01/2004 - "Dose-dependent efficacy of diclofenac-cholestyramine on pain and periarticular ossifications after total hip arthroplasty: a double-blind, prospective, randomised trial."

Related Drugs and Biologics

1.	Cholesterol
2.	Lovastatin (Mevacor)
3.	LDL Cholesterol
4.	Phenobarbital (Luminal)
5.	Diclofenac (SR 38)
6.	Bile Acids and Salts (Bile Acids)
7.	Lipoproteins (Lipoprotein)
8.	Charcoal (Charbon)
9.	leflunomide (Arava)
10.	Mesalamine (Mesalazine)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
3.	Arthroplasty
4.	Plasma Exchange
5.	Ligation